2-Pyridineacetamide, 4-[(3,3-difluorocyclobutyl)oxy]-N-[6-[(3R)-3-fluoro-4-[4-[(methylamino)carbonyl]-1H-1,2,3-triazol-1-yl]butyl]-3-pyridazinyl]-6-methyl-, hydrochloride (1:2)

IACS-6274, also known as IPN60090, is a potent, selective and orally active glutaminase inhibitor with potential antineoplastic and immunostimulating activities. IPN60090 selectively targets, binds to and inhibits human glutaminase, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate.